In this podcast, listen as 2 experts discuss novel therapies that target disease pathophysiology, with a focus on individualizing treatment to optimize outcomes for their patients with ITP. Claim your credit at pce.is/ITP.
In this second of two podcasts, listen as 2 experts discuss novel therapies that target disease pathophysiology, with a focus on individualizing treatment to optimize outcomes for their patients with ITP. Unique considerations of the drug and surgical options are discussed. This activity is available for CE/CME credit. Claim your credit at pce.is/ITP.
Contributors:
Hanny Al-Samkari, MD
Assistant Professor
Harvard Medical School
Attending Hematologist and Clinical Investigator
Division of Hematology Oncology
Massachusetts General Hospital
Boston, Massachusetts
Christopher Nelson, ACNP-BC, MBA
Nurse Practitioner
Hematology and Oncology
Avera Cancer Institute
Avera St Luke’s Hospital
Aberdeen, South Dakota
Dr Al-Samkari: consultant/advisor/speaker: Argenx, Forma, Moderna, Novartis, Rigel; consultant/research funding (paid to institution): Agios, Amgen, Dova/Sobi.
Mr Nelson: consultant/advisor/speaker: Amgen, AbbVie, AstraZeneca, Bristol-Myers Squibb/Celgene, Beigene, Incyte, Karyopharm, Rigel, Sanofi.